Home/Filings/4/0001437749-14-012510
4//SEC Filing

Furiex Pharmaceuticals, Inc. 4

Accession 0001437749-14-012510

CIK 0001484478operating

Filed

Jul 6, 8:00 PM ET

Accepted

Jul 7, 4:39 PM ET

Size

9.9 KB

Accession

0001437749-14-012510

Insider Transaction Report

Form 4
Period: 2014-07-02
COVINGTON PAUL S
Senior VP-Clinical Operations
Transactions
  • Disposition to Issuer

    Common Stock

    2014-07-0222,5230 total
  • Disposition to Issuer

    Stock Options (to buy)

    2014-07-0226,0000 total
    Exercise: $15.00Exp: 2021-05-09Common Stock (26,000 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2014-07-0237,9440 total
    Exercise: $13.16Exp: 2021-10-03Common Stock (37,944 underlying)
Footnotes (3)
  • [F1]Pursuant to the Agreement and Plan of Merger by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc. (the "Company") dated as of April 27, 2014 (the "Agreement"), each share of the Company's common stock was exchanged for $95.00 in cash, without interest, less any applicable withholding taxes ("Cash Consideration"), plus one contingent value right (a "CVR"), which represents the right to receive contingent payments of up to approximately $30.00 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods.
  • [F2]All options became 100% vested on June 11, 2014 in connection with the Agreement.
  • [F3]Pursuant to the Agreement, each stock option of the Company was exchanged for (A) an amount in cash equal to the product of (1) the total number of shares of the Company's common stock subject to the option immediately prior to the effective time multiplied by (2) the excess, if any, of the per Cash Consideration over the exercise price per share of common stock under the option and (B) one CVR multiplied by the total number of shares of common stock subject to the option (assuming full vesting of the option) had the Reporting Person exercised such option in full immediately prior to the effective time of the merger.

Issuer

Furiex Pharmaceuticals, Inc.

CIK 0001484478

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001484478

Filing Metadata

Form type
4
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 4:39 PM ET
Size
9.9 KB